2026 Could Be the Year Psychedelics Finally Break Through
Last reviewed and updated: June 23, 2026.
Key Takeaways
| MDMA therapy | FDA rejected 2024; Lykos Therapeutics pursuing path forward; multi-year minimum; access only through clinical trials now |
| Psilocybin timeline | Breakthrough Therapy designation granted; Phase 3 underway; realistic FDA approval 2027–2029 if trials succeed |
| State access now | Oregon Measure 109 licensed service centers operational; Colorado Prop 122 personal possession + home cultivation legal for adults 21+ |
| Legal today (U.S.) | IV ketamine (off-label, nationwide) and Spravato/esketamine (FDA-approved TRD, insurance-covered) are the only currently legal options |
| Outside U.S. | Jamaica (psilocybin never scheduled), Netherlands (truffle gray area), Portugal (decriminalized all drugs) |
The psychedelic medicine field is entering its most consequential year yet. Two companies are preparing to file for FDA approval of treatments that could reshape mental health care. Compass Pathways is developing COMP360, a psilocybin therapy for treatment resistant depression. Definium is advancing MM120, an LSD based treatment targeting generalized anxiety disorder and major depressive disorder. Wall Street analysts are calling 2026 “a very big year for psychedelics.” Both therapies could reach approval as early as 2027.
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
| Key Takeaway | Details |
|---|---|
| Lead Companies | Compass Pathways (COMP360) and Definium (MM120) |
| Target Conditions | Treatment resistant depression, anxiety, MDD, PTSD |
| Projected Approval Timeline | As early as 2027 |
| FDA Support | Commissioner Makary pledged rapid review of psychedelic data |
| Key Differentiator | COMP360 single session vs. Spravato’s ~10 sessions over six weeks |
| Remaining Hurdles | DEA rescheduling, state law updates, clinic scalability |
Lessons From the Lykos Setback
The FDA rejected Lykos Therapeutics’ MDMA therapy for PTSD in August 2024. The decision shook the industry. But the details told a more nuanced story. The agency focused its concerns on trial design, not on psychedelics as a drug class. That distinction matters enormously. Compass and Definium have built their late stage programs with those lessons in hand.
Compass plans several Phase III data readouts this quarter. Definium has three Phase III data drops on deck. RBC Capital Markets described these catalysts as a potential “tipping point” for the entire sector.
Washington Is Paying Attention
So will regulators cooperate? Signs point toward yes. FDA Commissioner Marty Makary pledged a rapid review of psychedelic therapy data last year. Health Secretary Robert F. Kennedy Jr. has also voiced support for expanding access to these treatments.
Analysts note the current administration’s willingness to rethink old norms could change how advisory committees evaluate psychedelic drugs. That shift could accelerate the timeline to approval.
The Gap Between Approval and Access
Even after the FDA acts, patients will not gain instant access. The DEA must reschedule psilocybin and LSD from Schedule 1. Each state then needs to update its own laws. About half have trigger laws that automatically follow federal guidance. The rest will require separate legislative action.
Delivery logistics present another real challenge. COMP360 sessions can last six hours. MM120 can take eight. Compare that to Spravato, which runs about two hours per visit. Clinics will need to rethink operations and staffing.
Despite those hurdles, analysts project both drugs could win approval by 2027. Compass also recently received FDA acceptance of an investigational drug application for COMP360 in PTSD. That indication alone could serve an estimated 13 million patients.
For those living with treatment resistant depression, anxiety or PTSD, this year’s clinical readouts may represent the beginning of a new era in mental health care.
Where Psychedelic Therapy Stands in Mid-2026
The psychedelic therapy landscape has shifted significantly in the first half of 2026. Here is where the major programs and regulatory pathways stand.
MDMA-assisted therapy: FDA rejection and what comes next. The FDA’s 2024 rejection of MAPS’s application for MDMA-assisted therapy for PTSD was a significant setback for the field. The FDA’s Complete Response Letter cited concerns about functional unblinding (participants and therapists can generally tell who received MDMA vs. placebo), the potential for abuse given MDMA’s recreational use history, and questions about the generalizability of the trial population. MAPS and its spinoff company Lykos Therapeutics have indicated they plan to continue working toward approval, potentially through additional trials designed to address the FDA’s methodological concerns. This is a 3–5 year pathway at minimum. The FDA rejection does not mean MDMA-assisted therapy is scientifically invalidated — the clinical effect sizes in the trials were substantial — but it does mean a longer road to legal access than the field had anticipated.
Psilocybin: the most active regulatory front. Psilocybin is currently the most clinically advanced psychedelic in the U.S. regulatory pipeline. Oregon’s Measure 109 licensed service centers are operational, and Colorado’s Prop 122 is building out its licensing framework for supervised use centers expected to open in 2025–2026. At the FDA level, psilocybin has Breakthrough Therapy designation for treatment-resistant depression (from both Compass Pathways and Usona Institute), which accelerates review. Phase 3 trials are underway. A realistic timeline for FDA approval of a psilocybin therapy product, if trials are successful, is 2027–2029. Multiple states including Washington, Minnesota, and Hawaii are considering state-level reform legislation.
Ketamine remains the only legally accessible psychedelic-class therapy. While the psilocybin and MDMA pipelines continue toward potential approval, ketamine (Schedule III, available for off-label prescribing) and esketamine/Spravato (FDA-approved for TRD since 2019) remain the only legally accessible psychedelic-adjacent therapies in the U.S. IV ketamine and Spravato are available through thousands of clinics and psychiatric practices nationally. For patients who cannot wait years for potential psilocybin or MDMA approval, ketamine therapy represents the current standard of care for treatment-resistant conditions within the psychedelic-assisted therapy framework.
Frequently Asked Questions
Is MDMA therapy legal in the United States?
No — the FDA rejected the application for MDMA-assisted therapy for PTSD in 2024. MDMA remains Schedule I. The development company (Lykos Therapeutics) is working on a path forward, but FDA approval is now a multi-year process at minimum. MDMA-assisted therapy is not available through any legal clinical pathway in the U.S. at this time outside of active clinical trials. Access through clinical trials is possible — check clinicaltrials.gov for open enrollment studies.
When will psilocybin therapy be legal federally?
A realistic timeline for FDA approval of a psilocybin-based therapy, if current Phase 3 trials are successful, is approximately 2027–2029. Psilocybin has Breakthrough Therapy designation from the FDA (for treatment-resistant depression), which accelerates the review process, but Phase 3 trial completion and FDA review still take years. In the meantime, state-level access is available: Oregon has licensed service centers operational under Measure 109; Colorado is building out its Prop 122 supervised use framework. These are state programs, not federal approval — psilocybin remains Schedule I federally.
What psychedelic therapies are legally available right now?
In the United States: (1) IV ketamine — available off-label at ketamine clinics nationally; not FDA-approved for depression but legally administered by licensed physicians; (2) Esketamine (Spravato) — FDA-approved for treatment-resistant depression and MDD with suicidal ideation; covered by insurance at certified providers; (3) Oregon psilocybin service centers — legal under state law for adults, facilitated sessions, no diagnosis required; (4) Colorado Prop 122 — personal possession and home cultivation legal for adults 21+; licensed healing centers in development. Outside the U.S.: Jamaica (psilocybin never scheduled), Netherlands (psilocybin truffles in a legal gray area), and some other jurisdictions offer legal or unscheduled access.
What is Breakthrough Therapy designation and why does it matter for psilocybin?
Breakthrough Therapy designation (BTD) is granted by the FDA to drugs that show preliminary evidence of substantial improvement over available therapies for serious conditions. It triggers more intensive FDA guidance during development, rolling review of trial data (so review can begin before the full application is submitted), and faster overall review timelines. Psilocybin has received BTD for treatment-resistant depression from both Compass Pathways and Usona Institute — indicating the FDA has seen preliminary evidence significant enough to warrant accelerated development. BTD does not guarantee approval, but it shortens the typical timeline. It’s the most significant regulatory marker of how seriously the FDA is taking psilocybin as a therapeutic candidate.
